Potential of polymeric nanoparticles in AIDS treatment and prevention

Expert Opinion on Drug Delivery

Volumn 8, Issue 1, 2011, Pages 95-112

  Khalil, Najeh Maissar ^a   Carraro, Emerson ^a   Cótica, Luiz Fernando ^b   Mainardes, Rubiana Mara ^a  

^a UNIVERSIDADE ESTADUAL DO CENTRO OESTE   (Brazil)

^b STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

AIDS; Antiretroviral drugs; Polymeric nanoparticles; Targeting

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NANOCAPSULE; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE KIDNEY FAILURE; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BLOOD TOXICITY; CD4+ T LYMPHOCYTE; COUGHING; CRYSTALLURIA; DIARRHEA; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; FANCONI RENOTUBULAR SYNDROME; FATTY LIVER; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOPOIETIC STEM CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE INFLAMMATION; INJECTION SITE NODULE; INSULIN RESISTANCE; KIDNEY TUBULE NECROSIS; LACTIC ACIDOSIS; LATENT VIRUS INFECTION; LIPOATROPHY; LIVER TOXICITY; MONOCYTE MACROPHAGE PRECURSOR CELL; MONONUCLEAR PHAGOCYTE; MYALGIA; NAUSEA; NEPHROLITHIASIS; NEPHROTOXICITY; NERVE DEGENERATION; NONHUMAN; ORTHOSTATIC HYPOTENSION; OSTEOPENIA; PANCREATITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PLASMA PROTEIN BINDING; PROTEINURIA; PRURITUS; RASH; REVIEW; SKIN MANIFESTATION; SUSTAINED DRUG RELEASE; TERATOGENICITY; UPPER RESPIRATORY TRACT INFECTION; VIRUS LATENCY; VIRUS LOAD; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTI-HIV AGENTS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG STABILITY; HIV INFECTIONS; HUMANS; NANOPARTICLES; POLYMERS; SOLUBILITY;

EID: 78650552831     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2011.543673     Document Type: Review

References (152)

1. AIDS Epidemic Update: November 2009. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO), 2009. Available from: Http://data.unaids. org/pub/Report/2009/JC1700-Epi-Update-2009-en.pdf [Last accessed 29 September 2010]
2. Levy JA. HIV and the pathogenesis of AIDS. 3rd edition. American Society of Microbiology Press, Washington, DC; 2007
3. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1989;339:33-9
4. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: Causes and consequences. J Pathol 2008;214:231-41 (Pubitemid 351160160)
5. Stevenson M. HIV-1 pathogenesis. Nat Med 2003;9:853-60 (Pubitemid 36889926)
6. Hel Z, McGhee JR, Mestecky J. HIV infection: First battle decides the war. Trends Immunol 2006;27:274-81 (Pubitemid 44183640)
7. Mellor JW, Rinaldo CR Jr, Gupto P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70
8. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002;53:557-93 (Pubitemid 34177896)
9. Schrager LK, D'Souza MP. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 1998;280:67-71
10. Richman DD, Margolis DM, Delaney M, et al. The challenge of finding a cure for HIV infection. Science 2009;323:1304-7
11. Chun TW, Justement JS, Moir S, et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: Implications for eradication of virus. J Infect Dis 2007;195:1762-4 (Pubitemid 46870248)
12. Alexaki A, Liu Y, Wigdahl B. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res 2008;6:388-400
13. De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 2007;33:307-20
14. Cote HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002;346:811-20
15. Cihlar T, Ray AS. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res 2010;85:39-58
16. Smith CJ, Olsen CH, Mocroft A, et al. The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study. AIDS 2008;22:47-56 (Pubitemid 350294877)
17. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009;23:1109-18
18. D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multi-cohort collaboration. Lancet 2008;371:1417-26
19. Herlitz LC, Mohan S, Stokes MB, et al. Tenofovir nephrotoxicity: Acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 2010: Published online 1 September 2010, doi:10.1038/ki.2010.318
20. De Clercq E. Tenofovir disoproxil fumarate (TDF): Discovery and clinical development. In: Kazmierski WM, editor, Antiviral drugs: Biology, chemistry, clinic. John Wiley & Sons, Inc.; 2010: In press
21. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010;51:963-72
22. de Bethune M-P. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989-2009). Antiviral Res 2010;85:75-90
23. Fundaro C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 2002;16:299-300 (Pubitemid 34118582)
24. Plosker GL, Noble S. Indinavir: A review of its use in the management of HIV infection. Drugs 2009;58:1165-203
25. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998;351:543-9 (Pubitemid 28077559)
26. Croxtall JD, Perry CM. Lopinavir/ Ritonavir: A review of its use in the management of HIV-1 infection. Drugs 2010;70:1885-915
27. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80 (Pubitemid 30038386)
28. Wensing AM, van Maarseveen NM, Nijhuis M. Fifteen years of HIV protease inhibitors: Raising the barrier to resistance. Antiviral Res 2010;85:59-74
29. McColl DJ, Chen X. Strand transfer inhibitors of HIV-1 integrase: Bringing in a new era of antiretroviral therapy. Antiviral Res 2010;85:101-18
30. Bartlett JG, Gallant JE. Drug information. In: 2004 Medical Management of HIV Infection. Baltimore, MD: Johns Hopkins Medicine Health Publishing Business Group 2004. p. 99, 240-5
31. Ndegwa S. Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1. Issues Emerg Health Technol 2007;110:1-8
32. RxList the internet drug index, RxList, Inc. Available from: Http://www.rxlist. com/cgi/generic/intelence-cp.htm [Accessed 30 September 10]
33. Sharma P, Garg S. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv Drug Deliv Rev 2010;62:491-502 This review discusses the application of polymer based nanotechnologies for anti-HIV drugs.
34. Ojewole E, Mackraj I, Naidoo P, Govender T. Exploring the use of novel drug delivery systems for antiretroviral drugs. Eur J Pharm Biopharm 2008;70:697-710 Critical review discussing various drug delivery systems for AIDS treatment.
35. Flexner C. HIV drug development: The next 25 years. Nat Rev Drug Discov 2007;6:959-66 (Pubitemid 350201786)
36. Pozniak A. Tenofovir: What have over 1 million years of patient experience taught us? Int J Clin Pract 2008;62:1285-93 (Pubitemid 351977619)
37. Li X, Chan KW. Transport, metabolism and elimination mechanisms of anti-HIV agents. Adv Drug Deliv Rev 1999;39:81-103 (Pubitemid 29430231)
38. Staszewski S, Miller V, Sabin C, et al. Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS 1999;13:367-73 (Pubitemid 29095099)
39. Sosnik A, Chiappetta DA, Carcaboso AM. Drug delivery systems in HIV pharmacotherapy: What has been done and the challenges standing ahead. J Control Release 2009;138:2-15 An important review that discusses how to target HIV reservoir by means of drug delivery systems.
40. Hochman JH, Chiba M, Nishime J, et al. Influence of P-glycoprotein on the transport and metabolismof indinavir in Caco-2 cells expressing cytochrome P-450 3A4. J Pharmacol Exp Ther 2000;292:310-18 (Pubitemid 30026387)
41. Schinkel AH. The roles of P-glycoprotein and MRP1 in the blood-brain and blood-cerebrospinal fluid barriers. Adv Exp Med Biol 2001;500:365-72
42. Croxtall JD, Keam SJ. Raltegravir: A review of its use in the management of HIV infection in treatment-experienced patients. Drugs 2009;69:1059-75
43. Fung HB, Guo Y. Enfuvirtide: A fusion inhibitor for the treatment of HIV infection. Clin Ther 2004;26:352-78 (Pubitemid 38457330)
44. Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet 2010;376:49-62
45. Lieberman-Blum SS, Fung HB, Bandres JC. Maraviroc: A CCR5-receptor antagonist for the treatment of HIV-1 infection. Clin Ther 2008;30:1228-50
46. Gazzard BG. British HIV association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy. HIV Med 2008;9:563-608
47. Saksena NK, Haddad DN. Viral reservoirs an impediment to HAART: New strategies to eliminate HIV-1. Curr Drug Targets Infect Disord 2003;3:179-206
48. Richman DD, Margolis DM, Delaney M, et al. The challenge of finding a cure for HIV infection. Science 2009;323:1304-7
49. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001;70:1-20 (Pubitemid 32144788)
50. Kreuter J. In: Swarbrick J, Boylan JC, editors, Nanoparticles. Marcel Dekker, New York; 1994. p. 10
51. Fattal E, Vauthier C. In: Swarbric J, Boylan JC, editors, Nanoparticles as drug delivery systems. Marcel Dekker, New York; 2002. p. 10
52. Oppenheim RC. Solid colloidal drug delivery systems: Nanoparticles. Int J Pharm 1981;8:217-34
53. Allemann E, Gurny R, Doelker E. Drug loaded nanoparticles preparation methods and drug targeting issues. Eur J Pharm Biopharm 1993;39:173-91 (Pubitemid 23361352)
54. Ubrich N, Schmidt C, Bodmeier R, et al. Oral evaluation in rabbits of cyclosporine-loaded Eudragit RS or RL nanoparticles. Int J Pharm 2005;288:169-75 (Pubitemid 39662725)
55. Hoffart V, Lamprecht A, Maincent P, et al. Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. J Control Release 2006;113:38-42 (Pubitemid 43818166)
56. Kawashima Y. Nanoparticulate systems for improved drug delivery. Adv Drug Deliv Rev 2001;47:1-2 (Pubitemid 32209228)
57. Lewis DH. In: Chasin M, Langer R, editors, Biodegradable polymers as drug delivery systems. Marcel Dekker, New York; 1990. p. 45
58. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Sci 2002;6:319-27
59. Vinogradov SV, Bronich TK, Kabanov AV. Nanosized cationic hydrogels for drug delivery: Preparation, properties and interactions with cells. Adv Drug Deliv Rev 2002;54:135-47
60. Gartner S, Markovits P, Markovitz DM, et al. The role of mononuclear phagocytes in HTLVIII/LAV infection. Science 1986;233:215-19 (Pubitemid 16008118)
61. Koenig S, Gendelman HE, Orenstein JM, et al. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 1986;233:1089-93 (Pubitemid 16032241)
62. McElrath MJ, Pruett JE, Cohn ZA. Mononuclear phagocytes of blood and bone marrow: Comparative roles as viral reservoirs in human immunodeficiency virus type 1 infections. Proc Natl Acad Sci USA 1989;86:675-9
63. Bagnarelli P, Valenza A, Menzo S, et al. Dynamics and modulation of human immunodeficiency virus type 1 transcript in vitro and in vivo. J Virol 1996;70:7603-13 (Pubitemid 26339065)
64. Aquaro S, Bagnarelli P, Guenci T, et al. Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus. J Med Virol 2002;68:479-88 (Pubitemid 35231773)
65. Garaci E, Caroleo MC, Aloe L, et al. Nerve growth factor is an autocrine factor essential for the survival of macrophages infected with HIV. Proc Natl Acad Sci USA 1999;96:14013-18
66. McGann KA, Collman R, Kolson DL, et al. Human immunodeficiency virus-I causes productive infections of macrophages in primary placental cell culture. J Infect Dis 1994;169:746-53 (Pubitemid 24102104)
67. Milman G, Sharma O. Mechanism of HIV/SIV mucosal transmission. AIDS Res Hum Retroviruses 1994;109:1305-12
68. Vanct-Wout AB, Kootstra NA, Mulder-Kampinga GA. Macrophage-tropic variants initiate human immunodeficiency virus type I infections after sexual, parenteral and vertical transmission. J Clin Invest 1994;94:2060-7
69. Stolnik S, Illum L, Davis SS. Long circulating microparticulate drug carriers. Adv Drug Deliv Rev 1995;16:195-214
70. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006;307:93-102 This review comments comprehensively on the pharmacokinetics of polymeric nanoparticles. (Pubitemid 41773257)
71. Roser M, Fisher D, Kissel T. Surface-modified biodegradable albumin nano-and microspheres II: Effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm 1998;46:255-63 (Pubitemid 29057671)
72. Schafer V, von Briesen H, Andreesen R, et al. Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: A possibility for antiviral drug targeting. Pharm Res 1992;9:541-46
73. Bender AR, Schafer V, Steffan AM, et al. Inhibition of HIV in vitro by antiviral drug-targeting using nanoparticles. Res Virol 1994;145:215-20 (Pubitemid 24244521)
74. Bender AR, von Briesen H, Kreuter J, et al. Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. Antimicrob Agents Chemother 1996;40:1467-71 (Pubitemid 26169056)
75. Shah LK, Amiji MM. Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. Pharm Res 2006;23:2638-45
76. Hillaireau H, Le Doan T, Besnard M, et al. Encapsulation of antiviral nucleotide analogues azidothymidine-triphosphate and cidofovir in poly(iso-butylcyanoacrylate) nanocapsules. Int J Pharm 2006;324:37-42 (Pubitemid 44566445)
77. Hillaireau H, Le Doan T, Appel M, Couvreur P. Hybrid polymer nanocapsules enhance in vitro delivery of azidothymidine-triphosphate to macrophages. J Control Release 2006;116:346-52 (Pubitemid 44827412)
78. Mainardes RM, Gremiao MP, Brunetti IL, et al. Zidovudine-loaded PLA and PLA-PEG blend nanoparticles: Influence of polymer type on phagocytic uptake by polymorphonuclear cells. J Pharm Sci 2009;98:257-67
79. Mainardes RM, Khalil NM, Gremiao MP. Intranasal delivery of zidovudine by PLA and PLA-PEG blend nanoparticles. Int J Pharm 2010;395:266-71
80. Destache CJ, Belgum T, Christensen K, et al. Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. BMC Infect Dis 2009;9:198-206 One of few papers that involves combination drug in polymeric nanoparticles.
81. Destache CJ, Belgum T, Goede M, et al. Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice. J Antimicrob Chemother 2010;65:2183-7
82. Löbenberg R, Kreuter J. Macrophage targeting of azidothymidine: A promising strategy for AIDS therapy. AIDS Res Hum Retroviruses 1996;12:1709-15 (Pubitemid 26424050)
83. Löbenberg R, Araujo L, von Briesen H, et al. Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i. v. injection to rats. J Control Release 1998;50:21-30 (Pubitemid 28044097)
84. Löbenberg R, Maas J, Kreuter J. Improved body distribution of 14C-labelled AZT bound to nanoparticles in rats determined by radioluminography. Drug Targets 1998;5:171-9 (Pubitemid 28176789)
85. Dembri A, Montisci MJ, Gantier JC, et al. Targeting of 3'-azido -3'- deoxythymidine (AZT)-loaded poly (isohexylcyanoacrylate) nanospheres to the gastrointestinal mucosa and associated lymphoid tissues. Pharm Res 2001;18:467-73 (Pubitemid 32592578)
86. Takakura Y, Hashida M. Macromolecular carrier systems for targeted drug delivery: Pharmacokinetic considerations on biodistribution. Pharm Res 1996;13:820-31 (Pubitemid 26227738)
87. Largent BL, Walton KM, Hoppe CA, et al. Carbohydrate-specific adhesion of alveolar macrophages to mannose derivatized surfaces. J Biol Chem 1984;259:1764-9
88. Haltiwanger RS, Hill RL. The ligand binding specificity and tissue localization of a rat alveolar macrophage lectin. J Biol Chem 1986;261:15696-702
89. Shao J, Ma JKH. Characterization of mannosylphospholipid liposome system for drug targeting to alveolar macrophages. J Drug Deliv Target Ther Agents 1997;1998:43-8 (Pubitemid 27146186)
90. Jain SK, Gupta Y, Jain A, et al. Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery. Nanomedicine 2008;4:41-8 (Pubitemid 351324205)
91. Kaur A, Jain S, Tiwary AK. Mannan-coated gelatin nanoparticles for sustained and targeted delivery of didanosine: In vitro and in vivo evaluation. Acta Pharm 2008;58:61-74 (Pubitemid 351419158)
92. Rao KS, Reddy MK, Horning JL, Labhasetwar V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials 2008;29:4429-38
93. Letendre SL, Ellis RJ, Ances BM, McCutchan JA. Neurologic complications of HIV disease and their treatment. Top HIV Med 2010;18:45-55
94. Grant I. Neurocognitive disturbances in HIV. Int Rev Psychiatry 2008;20:33-47 (Pubitemid 351210470)
95. Varatharajana L, Thomasb SA. The transport of anti-HIV drugs across blood-CNS interfaces: Summary of current knowledge and recommendations for further research. Antiviral Res 2009;82:A99-A109
96. Khalil NM, Mainardes RM. Colloidal polymeric nanoparticles and brain drug delivery. Curr Drug Deliv 2009;6:261-73
97. Mahajan SD, Roy I, Xu GX, et al. Enhancing the delivery of anti retroviral drug 'Saquinavir' across the blood brain barrier using nanoparticles. Curr HIV Res 2010;8:396-404
98. Wong HL, Chattopadhyay N, Wu XY, Bendayan R. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv Drug Deliv Rev 2010;18;62:503-17 Critical review discussing how nanotechnology improves brain antiretroviral delivery.
99. Koziara JM, Lockman PR, Allen DD, Mumper RJ. The blood-brain barrier and brain drug delivery. J Nanosci Nanotechnol 2006;6:2712-35
100. Olivier JC, Fenart L, Chauvet R, et al. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm Res 1999;16:1836-42 (Pubitemid 30040699)
101. Goppert TM, Muller RH. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparison of plasma protein adsorption patterns. J Drug Target 2005;13:179-87
102. Kreuter J. Application of nanoparticles for the delivery of drugs to the brain. Int Congr Ser 2005;1277:85-94 (Pubitemid 43693337)
103. Kreuter J, Shamenkov D, Petrov V, et al. Apolipoprotein-mediated transport of nanoparticles-bound drugs across the blood-brain barrier. J Drug Target 2002;10:317-25 (Pubitemid 34746313)
104. Kuo YC. Loading efficiency of stavudine on polybutylcyanoacrylate and methylmethacrylatesulfopropylmethacrylate copolymer nanoparticles. Int J Pharm 2005;290:161-72
105. Kuo YC, Chen HH. Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylatesulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier. Int J Pharm 2006;327:160-69
106. Kuo YC, Su FL. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylatesulfopropylmethacrylate, and solid lipid nanoparticles. Int J Pharm 2007;340:143-52
107. Kang YS, Bickel U, Pardridge WM. Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferring receptor. Drug Metab Dispos 1994;22:99-105 (Pubitemid 24045387)
108. Shin SU, Friden P, Moran M, et al. Transferrin-antibody fusion proteins are effective in brain targeting. Proc Natl Acad Sci USA 1995;92:2820-24
109. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001;47:65-81 (Pubitemid 32209233)
110. Mishra V, Mahor S, Rawat A, et al. Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J Drug Target 2006;14:45-53
111. Torchilin VP. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev 2008;60:548-58
112. Jeang KT, Xiao H, Rich EA. Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J Biol Chem 1999;274:28837-40 (Pubitemid 29477031)
113. Dennison SR, Baker RD, Nicholl ID, Phoenix DA. Interactions of cell penetrating peptide Tat with model membranes: A biophysical study. Biochem Biophys Res Commun 2007;363:178-82
114. Torchilin VP. Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers 2008;90:604-10
115. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 1999;285:1569-72 (Pubitemid 29420581)
116. Rao KS, Ghorpade A, Labhasetwar V. Targeting anti-HIV drugs to the CNS. Expert Opin Drug Deliv 2009;6:771-84
117. Chen X-Q, Fawcett JR, Rahman Y-E, et al. Delivery of nerve growth factor to the brain via the olfactory pathway. J Alzheimer's Dis 1998;1:35-44
118. Thorne RG, Emory CR, Ala TA, Frey WH. Quantitative assessment of protein transport to the rat olfactory bulb following intranasal administration: Implications for drug delivery. Brain Res 1995;692:278-82
119. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004;127:481-96 (Pubitemid 38950662)
120. Ross TM, Martinez PM, Renner JC, et al. Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: A non-invasive treatment strategy for multiple sclerosis. J Neuroimmunol 2004;151:66-77
121. Hanson LR, Frey WH. Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS. J Neuroimmune Pharmacol 2007;2:81-6
122. Yang Z, Huang Y, Gan G, Sawchuk RJ. Microdialysis evaluation of the brain distribution of stavudine following intranasal and intravenous administration to rats. J Pharm Sci 2005;94:1577-88 (Pubitemid 41168686)
123. Betbeder D, Sperandio S, Latapie JP, et al. Biovector nanoparticles improve antinociceptive efficacy of nasal morphine. Pharm Res 2000;17:743-8 (Pubitemid 30670641)
124. Zhang QZ, Zha L-S, Zhang Y, et al. The brain targeting efficiency following nasally applied MPEG-PLA nanoparticles in rats. J Drug Target 2006;14:281-90 (Pubitemid 44173294)
125. Al-Ghananeem AM, Saeed H, Florence R, et al. Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by AIDS viruses. J Drug Target 2010;18:381-8
126. Letvin NL. Correlates of immune protection and the development of a human immunodeficiency virus vaccine. Immunity 2007;27:366-9
127. Chun TW, Fauci AS. Latent reservoirs of HIV: Obstacles to the eradication of virus. Proc Natl Acad Sci USA 1999;96:10958-61
128. Copland MJ, Rades T, Davies NM, Baird MA. Lipid based particulate formulations for the delivery of antigen. Immunol Cell Biol 2005;83:97-105 (Pubitemid 40469317)
129. Saupe A, McBurney W, Rades T, Hook S. Immunostimulatory colloidal delivery systems for cancer vaccines. Expert Opin Drug Deliv 2006;3:345-54 (Pubitemid 43772710)
130. Parren PWHI, Marx PA, Hessell AJ, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001;75:8340-7
131. Gallichan WS, Rosenthal KL. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J Exp Med 1996;184:1879-90
132. Vogel FR, Powell MF, Alving CR. A compendium of vaccine adjuvants and excipients. In: Powell MF, Newman MJ, editors, Vaccine design: The subunit and adjuvant approach. Plenum Press, New York; 1995
133. Simon JK, Edelman R. Clinical evaluation of adjuvants. In: Schijns VEJC, O'Hagan DT, editors, Immunopotentiators in modern vaccines. Academic Press, Burlington, MA; 2006
134. Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev 2008;60:915-28
135. Wendorf J, Singh M, Chesko J, et al. A practical approach to the use of nanoparticles for vaccine delivery. J Pharm Sci 2006;95:2738-50 (Pubitemid 46093180)
136. He Q, Mitchell A, Morcol T, Bell SJD. Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2. Clin Diagn Lab Immunol 2002;9:1021-4 (Pubitemid 34988469)
137. Lutsiak ME, Kwon GS, Samuel J. Biodegradable nanoparticles delivery of a Th2-biased peptide for induction of Th1 immune responses. J Pharm Pharmacol 2006;58:739-47 (Pubitemid 43836161)
138. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997;28:5-24
139. O'Hagan DT, Singh M, Gupta RK. Poly(lactide-coglycolide) microparticles for the development of single-dose controlled-release vaccines. Adv Drug Deliv Rev 1998;32:225-46 (Pubitemid 28267411)
140. Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. Biodegradable poly (lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev 2005;57:391-410 (Pubitemid 39550967)
141. Sharp FA, Ruane D, Claass B, et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci USA 2009;106:870-5
142. Locher CP, Putnam D, Langer R, et al. Enhancement of a human immunodeficiency virus env DNA vaccine using a novel polycationic nanoparticle formulation. Immunol Lett 2003;90:67-70 (Pubitemid 37548459)
143. Cui Z, Patel J, Tuzova M, et al. Strong T cell type-1 immune responses to HIV-1 Tat (1-72) protein-coated nanoparticles. Vaccine 2004;22:2631-40 (Pubitemid 38757367)
144. Ataman-Onal Y, Munier S, Ganee A, et al. Surfactant-free anionic PLA coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models. J Control Release 2006;112:175-85
145. Lamalle-Bernard D, Munier S, Compagnon C, et al. Coadsorption of HIV-1 p24 and gp120 proteins to surfactant-free anionic PLA nanoparticles preserves antigenicity and immunogenicity. J Control Release 2006;115:57-67 (Pubitemid 44429985)
146. Guillon C, Mayol K, Terrat C, et al. Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits. Vaccine 2007;25:7491-501 (Pubitemid 47516619)
147. Castaldello A, Brocca-Cofano E, Voltan R, et al. DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination. Vaccine 2006;24:5655-69 (Pubitemid 43928193)
148. Wang X, Uto T, Sato K, et al. Potent activation of antigen-specific T cells by antigen-loaded nanospheres. Immunol Lett 2005;98:123-30 (Pubitemid 40409827)
149. Wang X, Uto T, Akagi T, et al. Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120. J Virol 2007;81:10009-16 (Pubitemid 350067704)
150. Wang X, Uto T, Akagi T, et al. Poly (gamma-glutamic acid) nanoparticles as an efficient antigen delivery and adjuvant system: Potential for an AIDS vaccine. J Med Virol 2008;80:11-9 (Pubitemid 350220084)
151. Himeno A, Akagi T, Uto T, et al. Evaluation of the immune response and protective effects of rhesus macaques vaccinated with biodegradable nanoparticles carrying gp120 of human immunodeficiency virus. Vaccine 2010;28:5377-85
152. Aline F, Brand D, Pierre J, et al. Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination. Vaccine 2009;27:5284-91